PMID- 28495322
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20221207
IS  - 2530-0172 (Electronic)
IS  - 2530-0164 (Linking)
VI  - 64
IP  - 5
DP  - 2017 May
TI  - Prevalence and control of type 2 diabetes mellitus among primary care physicians 
      in Spain. PRISMA Study.
PG  - 265-271
LID - S2530-0164(17)30098-8 [pii]
LID - 10.1016/j.endinu.2017.03.003 [doi]
AB  - OBJECTIVE: To describe the prevalence of known and ignored type 2 diabetes 
      mellitus (T2DM) among primary care physicians (PCP), as well as the treatment 
      used and the degree of metabolic control reached. MATERIAL AND METHODS: 
      Descriptive cross-sectional study on national level. The participants were 
      randomly selected PCPs, members of the redGDPS Foundation. A total of 495 PCP 
      were enrolled. Capillary HbA(1c) measurement was done with a A1CNow+((R)) device 
      and a diabetes-related survey specifically designed for the study was 
      administered to the participants. RESULTS: The total prevalence of T2DM was 11.1% 
      (95% CI 8.33-13.9) (known disease 8,1% and ignored disease 3.0%). The prevalence 
      of prediabetes was 16.2% (95% CI 13.0-19.4). A total of 62.5% of PCPs with known 
      T2DM reached HbA(1c)<7% and 15% had HbA(1c)>8.5%. Control of blood pressure 
      (BP<140/90mmHg) was reached in 87.5% and control of LDL cholesterol<130mg/dl with 
      no history of cardiovascular disease was reached in 88.6% of cases of known T2DM. 
      In the PCPs with a history of macrovascular disease, good control of LDL was 
      reached in 42.9% of the cases. A total of 12.5% were active smokers. A total of 
      71.4% of PCPs with known T2DM self-treated their own disease, usually with 2 or 
      more drugs (51.4%). The most commonly used drug was metformin (74.3%) followed by 
      iDPP4 (48.6%). CONCLUSIONS: PCPs with T2DM have better metabolic control than the 
      general population. It is necessary to study whether PCPs with T2DM may have 
      greater adherence to treatment and do they achieve a better metabolic control.
CI  - Copyright (c) 2017 SEEN. Publicado por Elsevier Espana, S.L.U. All rights reserved.
FAU - Franch-Nadal, Josep
AU  - Franch-Nadal J
AD  - Fundacion redGDPS, Espana; Equip d'Atencio Primaria Raval Sud, Institut Catala de 
      la Salut, Barcelona, Espana; DAP_cat, Unitat de Suport a la Recerca Barcelona 
      ciutat, IDIAP Jordi Gol, Barcelona, Espana; CIBER of Diabetes and Associated 
      Metabolic Diseases (CIBERDEM), Barcelona, Espana. Electronic address: 
      josep.franch@gmail.com.
FAU - Mediavilla-Bravo, Javier
AU  - Mediavilla-Bravo J
AD  - Fundacion redGDPS, Espana; Centro de Salud Burgos Rural, Sanidad de Castilla y 
      Leon (SACYL), Burgos, Espana.
FAU - Mata-Cases, Manuel
AU  - Mata-Cases M
AD  - Fundacion redGDPS, Espana; DAP_cat, Unitat de Suport a la Recerca Barcelona 
      ciutat, IDIAP Jordi Gol, Barcelona, Espana.
FAU - Mauricio, Didac
AU  - Mauricio D
AD  - Fundacion redGDPS, Espana; DAP_cat, Unitat de Suport a la Recerca Barcelona 
      ciutat, IDIAP Jordi Gol, Barcelona, Espana; Hospital Universitari Germans Trias i 
      Pujol, Badalona, Barcelona, Espana.
FAU - Asensio, David
AU  - Asensio D
AD  - Departamento Medico de Almirall, Barcelona, Espana.
FAU - Sarroca, Jordi
AU  - Sarroca J
AD  - Departamento Medico de Almirall, Barcelona, Espana.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Prevalencia y control de la diabetes mellitus tipo 2 entre los medicos de 
      Atencion Primaria de Espana. Estudio PRISMA.
DEP - 20170427
PL  - Spain
TA  - Endocrinol Diabetes Nutr
JT  - Endocrinologia, diabetes y nutricion
JID - 101698946
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Lipids)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - *Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*epidemiology/therapy
MH  - Dyslipidemias/drug therapy/epidemiology
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypertension/drug therapy/epidemiology
MH  - Hypoglycemic Agents/therapeutic use
MH  - Hypolipidemic Agents/therapeutic use
MH  - Lipids/blood
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Physicians, Primary Care/psychology/*statistics & numerical data
MH  - Prediabetic State/diagnosis/epidemiology
MH  - Prevalence
MH  - Sampling Studies
MH  - Self Care
MH  - Smoking/epidemiology
MH  - Spain/epidemiology
OTO - NOTNLM
OT  - Atencion Primaria
OT  - Diabetes mellitus tipo 2
OT  - HbA(1c)
OT  - Medicos
OT  - Physicians
OT  - Prevalence
OT  - Prevalencia
OT  - Primary Care
OT  - Type 2 diabetes mellitus
EDAT- 2017/05/13 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/05/13 06:00
PHST- 2017/01/04 00:00 [received]
PHST- 2017/03/19 00:00 [revised]
PHST- 2017/03/22 00:00 [accepted]
PHST- 2017/05/13 06:00 [entrez]
PHST- 2017/05/13 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - S2530-0164(17)30098-8 [pii]
AID - 10.1016/j.endinu.2017.03.003 [doi]
PST - ppublish
SO  - Endocrinol Diabetes Nutr. 2017 May;64(5):265-271. doi: 
      10.1016/j.endinu.2017.03.003. Epub 2017 Apr 27.